Assets

The company's long-term assets, primarily comprised of intangible assets and goodwill, appear to be experiencing a moderate level of amortization, which may indicate a need for strategic investments in research and development to maintain competitiveness. Meanwhile, the company's short-term assets, including cash and cash equivalents, have shown a slight decline, suggesting a potential need for more efficient management of working capital. Overall, the company's total assets and investments seem to be in a state of stability, but may require further analysis to determine the underlying drivers of this trend.

Shareholders Equity

The company's Shareholders Equity has experienced a significant decline, primarily driven by substantial losses incurred in the current and prior periods, which have eroded retained earnings. Furthermore, the Translation differences component has shown a notable increase, indicating potential exchange rate fluctuations affecting the company's foreign operations. The Share capital and Share premium components have remained relatively stable, suggesting that the company has not issued new shares or engaged in significant share buybacks, which could have otherwise impacted Shareholders Equity.

The value of Optomed Equity at the end of Q2 2026 is 21.7 million Euros. The predicted value of Optomed Equity at the end of Q2 2027 (e) is 16.6 million Euros. The expected change in one year is a decrease of 5.1 million Euros, which is a 23.5% decrease from the Q2 2026 value. The Optomed Equity is expected to decrease by 4.9 million Euros from 2025 to 2026, which is a 20.4% drop. From 2026 to 2027, the Equity is predicted to decrease by 6.2 million Euros, representing a 32.1% decline. The year-end values for Equity are 24.0 million Euros in 2025, 19.1 million Euros in 2026, and 13.9 million Euros in 2027.

*Future dividents are not included in prediction

Debt

The company's reliance on short-term debt is a concern, as it indicates a lack of long-term financing stability and may limit the company's flexibility in managing its cash flows. Furthermore, the high gearing ratio suggests that the company's profitability is heavily influenced by its debt levels, making it vulnerable to interest rate fluctuations and potentially limiting its ability to invest in growth initiatives. However, the equity ratio appears to be relatively stable, indicating that the company's shareholders have a significant stake in the business and may be able to provide support during periods of financial stress.

The Net Debt in Q2 2026 is -5.4 million Euros, and the predicted Net Debt in Q2 2027 (e) is 2.0 million Euros. The expected change in Net Debt from Q2 2026 to Q2 2027 (e) is an increase of 7.4 million Euros, which represents a 136.7% change. The Net Debt is expected to decrease by 6.6 million Euros from 2025 to 2026, which is a 77% decrease. From 2026 to 2027, the Net Debt is expected to increase by 6.5 million Euros, which is a 344% increase. The year-end Net Debt values for 2025, 2026, and 2027 are -8.5, -1.9, and 4.6 million Euros respectively.